For HR-positive and HER2-negative breast cancer, neoadjuvant endocrine therapy should be considered first and aromatase inhibitors should be given priority, in addition, the use of ovarian function suppressants should be included in premenopausal women 13,16. Here, CYP19A1 is linked to breast cancer.